Neuroprotective effects of Jitai tablet, a traditional Chinese medicine, on the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system

Evidence-based Complementary and Alternative Medicine

Volumn 2014, Issue , 2014, Pages

  Liu, Jia ^a   Gao, Jinlong ^a   Tu, Shaoang ^a   Xu, Shasha ^a   Liu, Ying ^a   Shang, Weihu ^a   Gu, Chenxin ^a   Huang, Yiyun ^b   Han, Mei ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE PLUS LEVODOPA; CHINESE DRUG; DOPAMINE 2 RECEPTOR; JITAI TABLET; NEUROPROTECTIVE AGENT; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR CHANGE; CHINESE MEDICINE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG MEGADOSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; LOW DRUG DOSE; MALE; MOTOR COORDINATION; MOUSE; MPTP-INDUCED PARKINSONISM; NEUROPROTECTION; NONHUMAN; ROTAROD TEST; SUBSTANTIA NIGRA;

EID: 84899495866     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2014/542383     Document Type: Article

References (36)

1. Toulouse A., Sullivan A. M., Progress in Parkinson's disease-where do we stand? Progress in Neurobiology 2008 85 4 376 392 2-s2.0-48349136909 10.1016/j.pneurobio.2008.05.003
2. Hunot S., Boissière F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., Hirsch E. C., Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996 72 2 355 363 2-s2.0-0343844458 10.1016/0306-4522(95)00578-1
3. Elsworth J. D., Roth R. H., Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Experimental Neurology 1997 144 1 4 9 2-s2.0-0031104698 10.1006/exnr.1996.6379
4. Nagatsua T., Sawadab M., L-DOPA therapy for Parkinson's disease: past, present, and future. Parkinsonism and Related Disorders 2009 15 1 S3 S8 2-s2.0-58149120928 10.1016/S1353-8020(09)70004-5
5. Davie C. A., A review of Parkinson's disease. British Medical Bulletin 2008 86 1 109 127 2-s2.0-44949138796 10.1093/bmb/ldn013
6. Fahn S., Levodopa and the progression of Parkinson's disease. The New England Journal of Medicine 2004 351 24 2498 2566 2-s2.0-19744378296 10.1056/NEJMoa033447
7. More S. V., Kumar H., Kang S. M., Advances in neuroprotective ingredients of medicinal herbs by using cellular and animal models of Parkinson's disease. Evidence-Based Complementary and Alternative Medicine 2013 2013 15 957875 10.1155/2013/957875
8. Li X. Z., Zhang S. N., Liu S. M., Recent advances in herbal medicines treating Parkinson's disease. Fitoterapia 2013 84 273 285 10.1016/j.fitote.2012. 12.009
9. Wang S.-P., Liu L., Wang L.-L., Jiang P., Zhang J.-Q., Zhang W.-D., Liu R.-H., Screening and analysis of the multiple absorbed bioactive components and metabolites in rat plasma after oral administration of Jitai tablets by high-performance liquid chromatography/diode-array detection coupled with electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2010 24 11 1641 1652 2-s2.0-77952910575 10.1002/rcm.4561
10. Wang S. P., Liu L., Wang L. L., Structural characterization and identification of major constituents in Jitai tablets by high-performance liquid chromatography/diode-array detection coupled with electrospray ionization tandem mass spectrometry. Molecules 2012 17 9 10470 10493
11. Liu Y., Han M., Liu X. D., Dopamine transporter availability in heroin-dependent subjects and controls: longitudinal changes during abstinence and the effects of Jitai tablets treatment. Psychopharmacology 2013 230 2 235 244
12. Przedborski S., Vila M., MPTP: a review of its mechanisms of neurotoxicity. Clinical Neuroscience Research 2001 1 6 407 418 2-s2.0-0001485756 10.1016/S1566-2772(01)00019-6
13. Li X. M., Ma H. B., Ma Z. Q., Li L. F., Xu C. L., Qu R., Ma S.-P., Ameliorative and neuroprotective effect in MPTP model of Parkinson's disease by Zhen-Wu-Tang (ZWT), a traditional Chinese medicine. Journal of Ethnopharmacology 2010 130 1 19 27 2-s2.0-77953812185 10.1016/j.jep.2010.03.020
14. Jackson L. V., Przedborski S., Protocol for the MPTP mouse model of Parkinson's disease. Nature Protocols 2007 2 1 141 151 2-s2.0-34347259269 10.1038/nprot.2006.342
15. Zhang H. N., An C. N., Zhang H. N., Pu X. P., Protocatechuic acid inhibits neurotoxicity induced by MPTP in vivo. Neuroscience Letters 2010 474 2 99 103 2-s2.0-77951207425 10.1016/j.neulet.2010.03.016
16. Chung Y. C., Kim S. R., Park J.-Y., Chung E. S., Park K. W., Won S. Y., Bok E., Jin M., Park E. S., Yoon S.-H., Ko H. W., Kim Y.-S., Jin B. K., Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 2011 60 6 963 974 2-s2.0-79952449932 10.1016/j.neuropharm.2011.01.043
17. Chen Z., Zhou X., Wu C. Y., Synthesis and iodine labelling of β -CIT' as a dopamine transporter imaging agent. Journal of Isotopes 2000 13 1 7 11
18. Xiong Z., Xu G., Chen Z. P., Regulation of a sapogenin from Rhizoma Anemarrhenae, ZMR on dopaminergic system in a chronic mdole of Parkinson's disease. Chinese Journal of Nuclear Medicine 2009 29 5 331 334
19. Kung M. P., Liu B. L., Yang Y. Y., Billings J. J., Kung H. F., A kit formulation for preparation of iodine-123-IBZM: a new CNS D-2 dopamine receptor imaging agent. Journal of Nuclear Medicine 1991 32 2 339 342 2-s2.0-0026026010
20. Luo D., Zhang Q., Wang H., Cui Y., Sun Z., Yang J., Zheng Y., Jia J., Yu F., Wang X., Wang X., Fucoidan protects against dopaminergic neuron death in vivo and in vitro. European Journal of Pharmacology 2009 617 1-3 33 40 2-s2.0-68549112705 10.1016/j.ejphar.2009.06.015
21. Rousselet E., Joubert C., Callebert J., Parain K., Tremblay L., Orieux G., Launay J.-M., Cohen-Salmon C., Hirsch E. C., Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiology of Disease 2003 14 2 218 228 2-s2.0-0142250855 10.1016/S0969-9961(03)00108-6
22. Iderberg H., Francardo V., Pioli E. Y., Animal models of L-DOPA-induced dyskinesia: an update on the current options. Neuroscience 2012 211 13 27 2-s2.0-84860621650 10.1016/j.neuroscience.2012.03.023
23. Chen Y. L., Yan B. Y., Deng Y. P., Pharmacology of Jitai tablets, a traditional Chinese medicine for detoxification. Chinese Journal of New Drug 2010 19 14 1229 1233
24. Li Z., Tang Y., Hua S., Efficacy of Jitai for protracted withdrawal symptoms in heroin dependent patients. Chinese Journal of Drug Dependence 2007 16 4 284 287
25. Xu G., Duan L., Wang Z., A double-blind clinical trial of Jitai tablets vs Lofexidine in the treatment of heroin withdrawal symptoms. Chinese Journal of Drug Dependence 2000 9 4 273 277
26. Hao S. Q., Zhao M., Zhang R. W., The effectiveness comparison of Jitai tablets versus methadone in community-based drug treatment: a 1 year follow-up study. Addictive Behaviors 2013 38 10 2596 2600
27. 123I] β -CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry 2003 74 3 294 298 2-s2.0-0037373417 10.1136/jnnp.74.3.294
28. Ravina B., Marek K., Eberly S., Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Movement Disorders 2012 27 11 1392 1397
29. Jia L., Zhao Y., Liang X.-J., Current evaluation of the millennium phytomedicine-ginseng (II): Collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Current Medicinal Chemistry 2009 16 22 2924 2942 2-s2.0-70349408655 10.2174/ 092986709788803204
30. 11C]raclopride. Movement Disorders 1997 12 1 33 38 2-s2.0-0031031846 10.1002/mds.870120107
31. 2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Movement Disorders 1990 5 1 55 59 2-s2.0-0025274995
32. Kim H., Neuroprotective herbs for stroke therapy in traditional eastern medicine. Neurological Research 2005 27 3 287 301 2-s2.0-17144372588 10.1179/016164105X25234
33. Kennedy D. O., Scholey A. B., Ginseng: potential for the enhancement of cognitive performance and mood. Pharmacology Biochemistry and Behavior 2003 75 3 687 700 2-s2.0-0042201867 10.1016/S0091-3057(03)00126-6
34. Park B. G., Jung H. J., Cho Y. W., Potentiation of antioxidative and anti-inflammatory properties of cultured wild ginseng root extract through probiotic fermentation. Journal of Pharmacy and Pharmacology 2013 65 3 457 464
35. Wang J., Xu H.-M., Yang H.-D., Du X.-X., Jiang H., Xie J.-X., Rg1 reduces nigral iron levels of MPTP-treated C57BL6 mice by regulating certain iron transport proteins. Neurochemistry International 2009 54 1 43 48 2-s2.0-59049094805 10.1016/j.neuint.2008.10.003
36. 2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: positron emission tomography studies with microdialysis in the conscious monkey brain. Journal of Neuroscience 2000 20 18 7067 7073 2-s2.0-0034666288